Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
1999 3
2000 1
2002 2
2003 2
2004 1
2006 1
2011 3
2012 3
2013 2
2014 1
2015 1
2017 1
2018 1
2019 2
2020 3
2021 4
2022 2
2023 3
2024 6
2025 4
2026 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
The following term was not found in PubMed: /
Page 1
Pirfenidone facilitates immune infiltration and enhances the antitumor efficacy of PD-L1 blockade in mice.
Qin W, Zou J, Huang Y, Liu C, Kang Y, Han H, Tang Y, Li L, Liu B, Zhao W, Yuan X. Qin W, et al. Oncoimmunology. 2020 Sep 22;9(1):1824631. doi: 10.1080/2162402X.2020.1824631. Oncoimmunology. 2020. PMID: 33457101 Free PMC article.
Co-administration of pirfenidone with PD-L1 blockades significantly delayed the tumor growth and increased survival, compared with the effect of either treatment alone. ...Our results collectively demonstrated that pirfenidone facilitated antitumor immunity a …
Co-administration of pirfenidone with PD-L1 blockades significantly delayed the tumor growth and increased survival, compared …
[A Case Report of Checkpoint Inhibitor Pneumonitis Caused by PD-1 Antibody-Safety and Effectiveness of Pirfenidone].
Yu H, Li J, Yu L, Cheng X, Han X, Zhang X. Yu H, et al. Zhongguo Fei Ai Za Zhi. 2021 Jul 20;24(7):519-525. doi: 10.3779/j.issn.1009-3419.2021.103.08. Epub 2021 Jun 17. Zhongguo Fei Ai Za Zhi. 2021. PMID: 34134189 Free PMC article. Review. Chinese.
After initial high-dose glucocorticoid pulse therapy, the lung computed tomography (CT) imaging and clinical symptoms of the patients were partially relieved, and then pirfenidone (300 mg tid) was given orally for more than 11 months. During the treatment of pirfenidone …
After initial high-dose glucocorticoid pulse therapy, the lung computed tomography (CT) imaging and clinical symptoms of the patients were p …
A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis.
Li Y, Huang H, Ye X, Zeng B, Huang F, Chen L. Li Y, et al. Medicine (Baltimore). 2024 Apr 19;103(16):e37808. doi: 10.1097/MD.0000000000037808. Medicine (Baltimore). 2024. PMID: 38640289 Free PMC article.
This study aimed to determine the clinical efficacy of combination therapy with glucocorticoids and pirfenidone for ICIP related to programmed cell death protein-1 (PD-1) inhibitors. We conducted a retrospective analysis of 45 patients with advanced non-small cell l …
This study aimed to determine the clinical efficacy of combination therapy with glucocorticoids and pirfenidone for ICIP related to p …
[Efficacy of combined treatment with pirfenidone and PD-L1 inhibitor in mice bearing ectopic bladder cancer xenograft].
Chen S, Zhang S, Fan W, Sun W, Liu B, Liu J, Guo Y. Chen S, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2024 Feb 20;44(2):210-216. doi: 10.12122/j.issn.1673-4254.2024.02.02. Nan Fang Yi Ke Da Xue Xue Bao. 2024. PMID: 38501405 Free PMC article. Chinese.
OBJECTIVE: To assess the efficacy of pirfenidone combined with PD-L1 inhibitor for treatment of bladder cancer in a mouse model and its effect on tumor immune microenvironment modulation. ...PD-L1 inhibitor and pirfenidone alone significantly increased …
OBJECTIVE: To assess the efficacy of pirfenidone combined with PD-L1 inhibitor for treatment of bladder cancer in a mouse mode …
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Maher TM, et al. JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355. JAMA. 2023. PMID: 37159034 Free PMC article.
INTERVENTIONS: Patients were randomized 1:1:1 to receive 600 mg of oral ziritaxestat, 200 mg of ziritaxestat, or placebo once daily in addition to local standard of care (pirfenidone, nintedanib, or neither) for at least 52 weeks. MAIN OUTCOMES AND MEASURES: The primary ou …
INTERVENTIONS: Patients were randomized 1:1:1 to receive 600 mg of oral ziritaxestat, 200 mg of ziritaxestat, or placebo once daily in addit …
The Role of Antifibrotic Therapy in Pulmonary Fibrosis and Lung Cancer: A Multicenter Retrospective Analysis.
Bertuccio FR, Baio N, Perrotta F, Lacedonia D, D'Agnano V, Bianco A, Scioscia G, Tondo P, Foschino Barbaro MP, Bortolotto C, Corsico AG, Stella GM. Bertuccio FR, et al. Biomedicines. 2025 Sep 21;13(9):2310. doi: 10.3390/biomedicines13092310. Biomedicines. 2025. PMID: 41007870 Free PMC article.
Methods: We retrospectively analyzed 61 patients from multiple Italian centers: 35 received antifibrotic therapy (pirfenidone or nintedanib) and 26 did not. Outcomes included OS from cancer diagnosis and post-treatment AE-ILD. ...AE-ILD occurred in 11.4% of antifibrotic-tr …
Methods: We retrospectively analyzed 61 patients from multiple Italian centers: 35 received antifibrotic therapy (pirfenidone or nint …
Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Tan J, Xue Q, Hu X, Yang J. Tan J, et al. J Transl Med. 2024 Jan 23;22(1):95. doi: 10.1186/s12967-024-04884-7. J Transl Med. 2024. PMID: 38263193 Free PMC article. Review.
They can prevent normal tissues from being damaged and destroyed by the immune response. While current studies have focused on PD-1/PD-L1 and CTLA-4, PD-1/PD-L1 may be the only effective immune checkpoint IPF treatment. This review discusses the applic …
They can prevent normal tissues from being damaged and destroyed by the immune response. While current studies have focused on PD-1/ …
Pirfenidone-Loaded Polymeric Micelles as an Effective Mechanotherapeutic to Potentiate Immunotherapy in Mouse Tumor Models.
Mpekris F, Papaphilippou PC, Panagi M, Voutouri C, Michael C, Charalambous A, Marinov Dinev M, Katsioloudi A, Prokopi-Demetriades M, Anayiotos A, Cabral H, Krasia-Christoforou T, Stylianopoulos T. Mpekris F, et al. ACS Nano. 2023 Dec 26;17(24):24654-24667. doi: 10.1021/acsnano.3c03305. Epub 2023 Dec 6. ACS Nano. 2023. PMID: 38054429 Free PMC article.
Ongoing research is actively exploring the use of immune checkpoint inhibitors to treat solid tumors by inhibiting the PD-1/PD-L1 axis and reactivating the function of cytotoxic T effector cells. Many types of solid tumors, however, are characterized by a dense and …
Ongoing research is actively exploring the use of immune checkpoint inhibitors to treat solid tumors by inhibiting the PD-1/PD …
Differential Effects of Antifibrotic Treatment on Outcome Prediction via Serial Matrix Metalloproteinase-Degraded C-Reactive Protein Neoepitope Levels in Idiopathic Pulmonary Fibrosis.
Seeliger B, Ruwisch J, Bülow Sand JM, Simões FB, Jessen H, Börner E, Fuge J, Sewald K, Welte T, Wendel-Garcia PD, Schupp JC, Leeming DJ, Bonella F, Prasse A. Seeliger B, et al. Chest. 2026 Apr;169(4):991-1005. doi: 10.1016/j.chest.2025.08.047. Epub 2025 Sep 29. Chest. 2026. PMID: 41033547 Free PMC article.
At baseline and within 6 months of nintedanib or pirfenidone treatment, serum concentrations of matrix metalloproteinase-degraded C-reactive protein neoepitope (CRPM), collagen III, and collagen 6 fragments, as well as procollagen 6, were measured. ...INTERPRETATION: Our r …
At baseline and within 6 months of nintedanib or pirfenidone treatment, serum concentrations of matrix metalloproteinase-degraded C-r …
47 results